Add to ORKGThe Author(s) 2014. This article is published with open access at Springerlink.com Introduction: Bortezomib, a novel proteasome inhibitor, is approved for the treatment of relapsed multiple myeloma (MM). Efficacy and safety of bortezomib is well known; however, it was necessary to validate the data in patient
AbstractBecause multiple myeloma (MM) remains incurable, new therapeutic approaches are needed. Prot...
Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple My...
AbstractThe development of the proteasome inhibitor bortezomib is a prime example of successful benc...
Bortezomib, a novel proteasome inhibitor, is approved for the treatment of relapsed multiple myeloma...
Ajai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA...
Copyright © 2015 Jing Lu et al. This is an open access article distributed under the Creative Common...
Copyright © 2014 Jae-Sook Ahn et al. This is an open access article distributed under the Creative C...
Despite intensive therapy, multiple myeloma (MM) remains an incurable disease, and novel treatment a...
Bortezomib (formerly PS-341) has been the first proteasome inhibitor to enter clinical trials in can...
INTRODUCTION: Bortezomib has significantly improved multiple myeloma (MM) response rates, but strate...
Refractory or relapsed Multiple Myeloma (MM) is a plasma cell neoplasia characterized by paraprotein...
Multiple myeloma remains incurable despite available therapies, and novel therapies that target both...
Proteasome inhibition represents a new anticancer approach, with the potential effect of arresting t...
International audienceProteasome inhibitors and immunomodulatory drugs have contributed to the drama...
The treatment of multiple myeloma has evolved significantly over the past 2 decades due to the use o...
AbstractBecause multiple myeloma (MM) remains incurable, new therapeutic approaches are needed. Prot...
Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple My...
AbstractThe development of the proteasome inhibitor bortezomib is a prime example of successful benc...
Bortezomib, a novel proteasome inhibitor, is approved for the treatment of relapsed multiple myeloma...
Ajai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA...
Copyright © 2015 Jing Lu et al. This is an open access article distributed under the Creative Common...
Copyright © 2014 Jae-Sook Ahn et al. This is an open access article distributed under the Creative C...
Despite intensive therapy, multiple myeloma (MM) remains an incurable disease, and novel treatment a...
Bortezomib (formerly PS-341) has been the first proteasome inhibitor to enter clinical trials in can...
INTRODUCTION: Bortezomib has significantly improved multiple myeloma (MM) response rates, but strate...
Refractory or relapsed Multiple Myeloma (MM) is a plasma cell neoplasia characterized by paraprotein...
Multiple myeloma remains incurable despite available therapies, and novel therapies that target both...
Proteasome inhibition represents a new anticancer approach, with the potential effect of arresting t...
International audienceProteasome inhibitors and immunomodulatory drugs have contributed to the drama...
The treatment of multiple myeloma has evolved significantly over the past 2 decades due to the use o...
AbstractBecause multiple myeloma (MM) remains incurable, new therapeutic approaches are needed. Prot...
Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple My...
AbstractThe development of the proteasome inhibitor bortezomib is a prime example of successful benc...